The Partnership between the UAB Comprehensive Cancer Center (CCC), Tuskegee University (TU), and Morehouse School of Medicine (MSM) presents a unique opportunity to build on our successful accomplishments in training and education of the pipeline of future cancer research scientists, with emphasis on underrepresented racial/ethnic minorities. For this U54 application, The evaluation will be conducted by a team of evaluators representing each partnering institution, who meet monthly to discuss progress, issues, and solutions: Dr. Isabel Scarinci (UAB CCC), Dr. Desiree Rivers (MSM), and Mr. Lecarde Webb (TU). Although they will work together, each will be primarily responsible for specific Cores and Shared Resources. This team makes recommendations to be implemented administratively by the Principal Investigators with the advice, guidance, and direction of the Executive Committees (ECs) at each institution, the Partnership Leadership Committee (PLC), the Internal Advisory Committee, and the Program Steering Committee. These four committees also provide guidance to the PE Core members on adjustments to evaluation activities. Each Core and Shared Resource will have its own evaluation plan/worksheet outlining the evaluation questions for each specific aim, tasks, data collection tools, person responsible for each task, and timeline. The evaluator for each component will generate quarterly reports to be discussed with the ECs and the PLC. It should be noted that, although each component will have its own evaluation plan, an integrated evaluation process will be conducted to synergize all components to achieve the long-term outcomes.

Public Health Relevance

The primary responsibility of the Planning and Evaluation (PE) Core is to evaluate the impact of research projects, cores, and shared resources of the Partnership in achieving its programmatic goal of eliminating cancer health disparities. Given the participatory and complex nature of the tripartite Partnership between MSM, TU, and the UAB CCC, we plan to implement, for the entire project, a participatory, mixed-method, triangulated, formal process, impact, and outcomes evaluation plan.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54CA118948-11
Application #
9211119
Study Section
Special Emphasis Panel (ZCA1-SRB-X (A1))
Project Start
Project End
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
11
Fiscal Year
2016
Total Cost
$35,852
Indirect Cost
$11,463
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Luo, Yanzhuo; Li, Bingjin; Zhang, Guangxin et al. (2018) Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without EGFR Mutations or ALK Fusion. J Cancer 9:1096-1105
Wang, Chiung-Min; Yang, William H; Liu, Runhua et al. (2018) FOXP3 Activates SUMO-Conjugating UBC9 Gene in MCF7 Breast Cancer Cells. Int J Mol Sci 19:
Moore, Justin Xavier; Royston, Kendra J; Langston, Marvin E et al. (2018) Mapping hot spots of breast cancer mortality in the United States: place matters for Blacks and Hispanics. Cancer Causes Control :
Akinyemiju, Tomi; Moore, Justin Xavier; Pisu, Maria et al. (2018) A Prospective Study of Obesity, Metabolic Health, and Cancer Mortality. Obesity (Silver Spring) 26:193-201
Akinyemiju, Tomi; Moore, Justin Xavier; Judd, Suzanne E et al. (2018) Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget 9:16099-16109
Piyathilake, Chandrika J; Badiga, Suguna; Borak, Samuel G et al. (2017) A higher degree of expression of DNA methyl transferase 1 in cervical cancer is associated with poor survival outcome. Int J Womens Health 9:413-420
Williams, Samuel K; Braxton, Joanne M; Gosdin, Melissa et al. (2017) Evidence-Based Care for the Elderly: Uses of ""the Grandmother Principle"". J Health Care Poor Underserved 28:7
Gao, Song; Wang, Yicun; Wang, Meng et al. (2017) MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer. Oncotarget 8:41451-41464
Jia, Xu; Shanmugam, Chandrakumar; Paluri, Ravi K et al. (2017) Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. Oncotarget 8:20198-20212
Zhang, Yifan; Li, Bingjin; Zhang, Xingyi et al. (2017) CD24 is a genetic modifier for risk and progression of prostate cancer. Mol Carcinog 56:641-650

Showing the most recent 10 out of 193 publications